Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6895
Source ID: NCT00232583
Associated Drug: Metformin
Title: Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00232583/results
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Metformin|DRUG: Insulin|DRUG: Metfomin|DRUG: Pioglitazone|DRUG: glyburide
Outcome Measures: Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve), C-peptide AUC during a 3-hours mixed meal challenge testing, 72 months | Secondary: Insulin Sensitivity as Measure be Matsuda Index, C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square \[(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity., 72 months|Bet-cell Function Measured by Disposition Index, Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity, 72 months|Weight, Body Weight, 72 months|Inflammatory Markers - hsCRP, Inflammatory markers - hsCRP (C reactive protein), 72 months|Inflammatory Markers -Fibrinogen, Inflammatory markers - Fibrinogen, 72 months|Inflammatory Markers - PAI-1, Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1), 72 months|Quality of Life Survey (QoL) - Current Health Perception, Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago., 72 months|Quality of Life Survey (QoL) - Treatment Satisfaction, Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied., 72 months|Quality of Life Survey (QoL) - Treatment Impact, Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied., 72 months|Quality of Life Survey (QoL) - Social or Vocational Worry, Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time., 72 months|Quality of Life Survey (QoL) - Hypoglycemia Fear, Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry, 72 months|Quality of Life Survey (QoL) - Glycemia Control Perception, Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled., 72 months|Quality of Life Survey (QoL) - Lifestyle Flexibility, Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice., 72 months|Quality of Life Survey (QoL) - Social Stigma, Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree., 72 months|Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment, Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied., 72 months|Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment, Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing., 72 months
Sponsor/Collaborators: Sponsor: University of Texas Southwestern Medical Center
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 58
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2003-11
Completion Date: 2011-12
Results First Posted: 2015-05-28
Last Update Posted: 2017-12-14
Locations: University of Texas Southwestern, Dallas, Texas, 75390, United States
URL: https://clinicaltrials.gov/show/NCT00232583